Skip to main content

Table 4 Study description, recruitment outcomes and three derived recruitment performance metrics for 8 observational studies

From: Early experience with an opt-in research register - Scottish Health Research Register (SHARE): a multi-method evaluation of participant recruitment performance

Study name

Region(s) Involved

Study Inclusion & Exclusion Criteria

No. Requested by researchers

No. Identified in EHRs

No. Provided by SHARE to Research Team

No. Recruited

Percentage Identified and Recruited

Percentage Provided and Recruited

Percentage Fulfilled

Q

West

Inclusion:

• Age: 30–75

• Healthy

Exclusion:

• History of peptic ulcer disease

• History of Barrett’s oesophagus

• Previous H. pylori eradication

• Current use of PPIa/H2 blockers

• PPI use within last 12 months

• Upper GI cancer

• Pregnancy

150

1565

243

134

8.6

55.1

89.3

R

East

Inclusion:

• Aged 60–85

• Fluent in English

• Able to read

• Reliable study partner/informant

Exclusion:

• Dementia or any degenerative brain disorder

• Brain disease

• On cholinesterase inhibitors and/or memantine

• Receiving daily medications with the potential to affect cognition such as sedatives, pain medications, or anticonvulsants within 30 days

• Familial autosomal dominant Alzheimer’s disease or other familial dementing diseases

• Uncontrolled or untreated thyroid problems

• Clinically significant vitamin B12 or folic acid deficiency

• Chromosome21trisomy

• History within the past 2 years or current diagnosis of significant psychiatric illness

• History within the last 5 years of a serious infectious disease affecting the brain or head trauma resulting in protracted loss of consciousness

• Contraindications for MRI

• Major surgery, requiring general anaesthesia within 8 weeks or has not recovered

• Exposure to ionizing radiation

• Learning disability

• Currently participating in any interventional studies

• Currently participating in non-interventional study that involves exposure to radiation or neuropsychological testing

• History within the last 5 years of any type of cancer

• Currently on regular Vitamin B injections

• Currently taking anti-seizure medications

• Currently taking co-codamol or dihydrocodeine

• Currently taking opioids

• Currently taking benzodiazepines

• Stroke

• Blindness

• Deafness or significant hearing impairment

• Seizures

250

2365

700

91

3.8

13.0

36.4

S

All

Inclusion:

• Age: ≥16 years

• Diagnosis within the last 20 months of type 1diabetes or non-type 1 diabetes treated with diet non-type 1 diabetes on metformin monotherapy only

• Able to give informed consent

Exclusion:

• Non-type 1 diabetes on any oral hypoglycaemic agent other than metformin and who have had a prescription in the last 6 months

• Non-type 1 diabetes treated with an injectable therapy and who have had a prescription in the last 6 months

• Gestational diabetes

6000

3828

1040

246

6.4

23.7

4.1

T

East

Inclusion:

• Age: ≥70

• Heart Failure (NYHAb class II to IV)

• On frusemide) and ACE-ic

Exclusion:

• Living in nursing or residential home accommodation

30

99

36

19

19.2

52.8

63.3

U

East

Inclusion:

• Age: > 40

• COPD

Exclusion:

• Implemented during investigator screening

150

113

82

21

18.6

25.6

14.0

V

West

Inclusion:

• Age: 20–39

Exclusion:

• Insulin dependent diabetes

• Diseases of the Nervous System 1

• Diseases of the Nervous System 2

• Congenital malformations of the nervous system

• Inability to give informed consent

• Mental retardation

• Alzheimer’s Disease

• Other degenerative diseases of the CNSd, not elsewhere specified

• Other degenerative disorders of nervous system in diseases classified elsewhere

• myotonic dystrophy or other muscular dystrophy

• family history of myotonic dystrophy and never tested

• Severe concurrent medical condition, e.g. cardiac failure or respiratory failure

• Contraindications to MRIe

• History of major head trauma with loss of consciousness greater than a few minutes or with significant medical sequelae

8

66

10

7

10.6

70.0

87.5

W

East

Inclusion:

• Age: 40–85

• Type 2 Diabetes

• Blood pressure ≤ 140/80 mmHg

• HbA1ch value ≤64 mmol/mol

Exclusion:

• Blood pressure > 140/80 mmHg

• eGFRi < 60

• Atrial fibrillation

• Heart failure

• Peripheral vascular disease

• Stroke

• TIAj

• Ischaemic heart disease

• Inability to consent

30

238

24

5

2.1

20.8

16.7

X

West

Inclusion:

• Male or female ≥18 years of age

• Residing in Scotland

• Diagnosis of Bipolar Disorder

• At least three months lithium treatment in the past or current lithium treatment

190

16

6

6

37.5

100.0

3.2

Median (Interquartile)

150 (30–190)

238 (99–1565)

82 (24–243)

21 (7–91)

9.8 (6.4–18.6)

52.7 (23.7–55.1)

36.4 (14.0–63.3)

  1. aProton-pump inhibitor
  2. bthe New York Heart Association Functional Classification
  3. cangiotensin-converting-enzyme inhibitor
  4. dcentral nervous system
  5. emagnetic resonance imaging
  6. hHemoglobin A1c
  7. iestimated Glomerular Filtration Rate
  8. jTransient Ischaemic Attack